Company Profile

Oncorus, Inc. is a preclinical-stage biopharmaceutical company focused on the intravenous administration of self-amplifying RNA to transform outcomes for cancer patients. The Company's two product candidates from its self-amplifying RNA platform are ONCR-021 and ONCR-788. ONCR-021, a lead product candidate that is an IV administered viral RNA encoding an optimized genome of Coxsackievirus 21A (CVA21), is encapsulated within a lipid nanoparticle (LNP). The Company intends to develop ONCR-021 for non-small cell lung cancer, renal cell carcinoma, melanoma, anaplastic thyroid cancer, and hepatocellular carcinoma. The Company is also developing ONCR-788, which encodes for a modified version of the Seneca Valley Virus (SVV). The Company designed its HSV platform, including product candidate ONCR-719, to overcome the limitations in potency and in the ability to stimulate anti-tumor immunity that have both been encountered by previous viral immunotherapies and other immuno-oncology therapies.

Employees

Sector

Biotechnology & Medical Research

More about the company

23-08-03	Oncorus, Inc. Announces Executive Changes	CI
23-08-03	Oncorus, Inc. Announces Changes to Its Board	CI
23-08-03	Oncorus, Inc. Announces Executive Changes	CI
23-07-28	Oncorus, Inc. Announces Board Changes	CI
23-07-19	Oncorus, Inc. Announces Resignation of Douglas M. Fambrough III from its Board of Directors as Well as Compensation Committee, Effective July 20, 2023	CI
23-07-19	Oncorus, Inc. Enters into Lease Termination Agreement with IQHQ-4 Corporate, LLC	CI
23-06-23	Oncorus, Inc.(OTCPK:ONCR) dropped from S&P TMI Index	CI
23-06-20	Oncorus, Inc.(OTCPK:ONCR) dropped from NASDAQ Composite Index	CI
23-06-07	Oncorus Announces Management Changes	CI
23-06-07	Oncorus Appoints Brian Shea as Interim Chief Executive Officer	CI
23-06-02	Debt Limit Deal Approval, Jobs Data in Focus Amid Higher Exchange-Traded Funds, Equity Futures Pre-Bell Friday	MT
23-06-01	Oncorus to Lay Off Almost Entire Workforce -- Shares Slump After-Hours	MT
23-06-01	Stocks to Watch : Lululemon, Lava Therapeutics, Tilly's, Oncorus	DJ

22-12-01	Chardan Downgrades Oncorus to Neutral From Buy After Announced Pipeline Reprioritization, Workforce Reduction; Withdraws Price Target	MT
22-06-15	Chardan Research Initiates Oncorus at Buy with $5 Price Target	MT
22-05-19	Piper Sandler Adjusts Oncorus' Price Target to $12 From $40, Reiterates Overweight Rating	MT
22-03-28	HC Wainwright Starts Oncorus at Buy With $7 Price Target	MT
22-03-10	Maxim Group Adjusts Oncorus Price Target to $7 From $20, Maintains Buy Rating	MT

23-07-19	Oncorus : Termination of Material Agreement - Form 8-K	PU
23-07-06	Nanocap Potential Breakout Watchlist (EPAZ, GCAN, IQST, ONCR)	AQ
23-06-01	ONCORUS, INC. : Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
23-06-01	Oncorus Announces Workforce Reduction Plan	AQ
23-06-01	Oncorus Announces Workforce Reduction Plan	GL

Manager	Title	Age	Since
Gina Balderas COO	Chief Operating Officer	-	-
Stephanie Duncanson PRN	Corporate Officer/Principal	-	-
Chris German AUD	Comptroller/Controller/Auditor	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
6/6/23	Brian Shea	Other	Chief Executive Officer	61,085	0.2341%
12/28/22	Deerfield Management Co. LP	Sell	Company	336,235	1.2945%
12/22/22	Deerfield Management Co. LP	Sell	Company	73,384	0.2825%

Oncorus, Inc. Stock

Stocks

ONCR

US68236R1032

Biotechnology & Medical Research

Latest news : Oncorus, Inc.

Analysts' recommendations: Oncorus, Inc.

Press Releases: Oncorus, Inc.

Quotes and Performance

Managers and Directors: Oncorus, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ONCORUS, INC.	-3.08%	+869.23%	-	-	3.29M
WUXI APPTEC CO., LTD.	+2.35%	+2.74%	+33.41%	+79.20%	56.54B
ARGENX SE	-0.21%	-7.38%	+25.34%	+63.02%	53.6B
BIONTECH SE	-2.44%	+1.40%	-15.74%	-16.80%	22.91B
INSMED INCORPORATED	-2.85%	-7.78%	-8.09%	+346.36%	21.37B
WUXI BIOLOGICS (CAYMAN) INC.	+2.49%	-0.92%	+20.31%	-12.15%	20.27B
GENMAB A/S	+0.79%	-1.06%	+29.29%	-33.32%	17.56B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.58%	-5.88%	+16.30%	+540.37%	14.75B
EXELIXIS, INC.	-5.25%	-4.23%	+46.41%	+169.05%	13.33B
PHARMAESSENTIA CORPORATION	+3.41%	-6.61%	+163.08%	+280.43%	13.53B
Average	-0.42%	-3.79%	+34.48%	+157.35%	25.98B
Weighted average by Cap.	+0.23%	-2.96%	+28.67%	+119.98%